Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Oxford University spinout Mind Foundry is developing software that will help organisations solve problems by unlocking insights hidden deep within their data.

The Oxford team uses advanced machine learning algorithms to solve problems which can only currently be solved by teams of data scientists, or which are currently unsolvable.

Mind Foundry has raised £1.2m in seed funding from private investors and investment company Oxford Sciences Innovation to commercialise the technology.

The company’s technology is based on advanced algorithms and techniques developed by Professors Stephen Roberts and Michael Osborne, who lead Machine Learning research at Oxford’s Department of Engineering Science.

Mind Foundry will build on over 25 years of academic research and applied commercial consulting engagements within the Machine Learning Research Group, a specialist research team within Information Engineering at the University’s Department of Engineering Science.

Stephen Roberts commented: “We live in an era in which the success of organisations and advances in science and technology are increasingly reliant on the fast and accurate analysis of data. But driving these advances is a deluge of data which is outstripping the computational ability to process it, let alone act upon it. We live in an age of big data – but not necessarily big insight. Mind Foundry has the capability to turn this data into actionable insight.” 

Michael Osborne said: “Mind Foundry will enable decision-making from insights generated while the data is being created. This will take organisations beyond business intelligence query tools towards predictive modelling. This is particularly applicable to real-time business recommendations, high-frequency trading, or warning of potential problems or maintenance requirements in industrial systems.”

Mind Foundry’s machine learning techniques have been used by leading firms in the energy, financial services, engineering and manufacturing sectors including BAE Systems, Rolls-Royce and Santos.

The Oxford researchers have won multiple awards including the Rolls-Royce Chairman’s Award for Technical Innovation, the BAE Systems Chairman’s Award and the Google Impact Challenge.

Chief Executive David Pool joins the company from data insight analytics company Ijento and predictive analytics company i4C. “Mind Foundry’s base in Oxford gives us the opportunity to work with some of the finest talent in Machine Learning,” he said.

Isis Innovation managing director Linda Naylor said: “Oxford is recognised as amongst the world’s leading institutions in data analysis. We expect Mind Foundry to be at the forefront of what has been dubbed the ‘algorithm economy’ – the use of algorithms to manage data and guide decision-making.”

Similar stories

Major grant to strengthen research and benefit patients

Oxford University Hospitals (OUH) has made a grant of £11.5 million to the University of Oxford, which the University will match with other funding, to allow the development of major clinical research facilities which have the potential to support the introduction of innovative and ground-breaking treatments for patients.

Dr Lennard Lee awarded ACP McElwain Prize for contributions to medical oncology

Dr Lee (Department of Oncology) received the award to acknowledge his contributions during the COVID-19 pandemic, through the establishment of the UK Coronavirus Cancer Monitoring Project.

Oxford joins forces with 11 universities to launch social impact investment fund

The University of Oxford has joined forces with 11 leading universities to create Impact 12, an impact investment fund to support mission-led university ventures.

Ivermectin to be investigated as a possible treatment for COVID-19 in the PRINCIPLE trial

From today, ivermectin is being investigated in the UK as part of the Platform Randomised Trial of Treatments in the Community for Epidemic and Pandemic Illnesses (PRINCIPLE), the world’s largest clinical trial of possible COVID-19 treatments for recovery at home and in other non-hospital settings.

Potential for radiotherapy and VTP multimodality therapy for prostate cancer

A recent collaborative study from the University of Oxford has investigated the potential benefit of a combined therapy approach to prostate cancer treatment, using radiotherapy and vascular targeted photodynamic therapy (VTP), which could lead to first-in-man early phase clinical trials.

Latest data on immune response to COVID-19 reinforces need for vaccination, says Oxford-led study

A new study led by the University of Oxford has found that previous infection, whether symptomatic or asymptomatic, does not necessarily protect you long-term from COVID-19, particularly against new Variants of Concern.